Brokerages Set LivaNova PLC (NASDAQ:LIVN) Price Target at $81.38

LivaNova PLC (NASDAQ:LIVN) has earned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $81.3750.

Several analysts have recently commented on the company. Robert W. Baird reduced their target price on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. KeyCorp increased their price target on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, June 22nd. Barclays upped their price objective on shares of LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Freedom Capital raised shares of LivaNova to a “hold” rating in a research note on Tuesday, June 30th. Finally, Zacks Research upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st.

LivaNova Trading Down 0.5%

LIVN opened at $81.05 on Friday. LivaNova has a fifty-two week low of $41.01 and a fifty-two week high of $85.27. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11. The firm has a market capitalization of $4.45 billion, a price-to-earnings ratio of 41.56 and a beta of 0.86. The company’s 50 day moving average price is $78.96 and its two-hundred day moving average price is $70.06.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The firm had revenue of $362.26 million for the quarter, compared to the consensus estimate of $346.05 million. During the same period in the previous year, the business earned $0.88 EPS. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, research analysts predict that LivaNova will post 3.73 earnings per share for the current year.

Insider Transactions at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the sale, the director directly owned 7,228 shares of the company’s stock, valued at approximately $547,521. The trade was a 19.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.35% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of LIVN. Millennium Management LLC lifted its holdings in LivaNova by 17.3% during the fourth quarter. Millennium Management LLC now owns 3,484,082 shares of the company’s stock worth $214,376,000 after acquiring an additional 514,268 shares during the period. Wellington Management Group LLP grew its stake in LivaNova by 83.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after purchasing an additional 1,067,349 shares during the period. Vanguard Group Inc. increased its position in shares of LivaNova by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 2,332,051 shares of the company’s stock valued at $143,491,000 after purchasing an additional 34,812 shares during the last quarter. AQR Capital Management LLC increased its position in shares of LivaNova by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 2,155,142 shares of the company’s stock valued at $132,606,000 after purchasing an additional 496,165 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of LivaNova by 2.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,826,248 shares of the company’s stock worth $116,067,000 after purchasing an additional 38,320 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.